Abstract: The present invention provides use of EB1 as a biomarker for predicting the response of a brain neoplasm to a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro; and wherein pyridinyl is optionally substituted by amino or halogen; R1 represents hydrogen or cyano-lower alkyl; or a pharmaceutically acceptable derivative thereof, and wherein the prefix lower denotes a radical having up to and including a maximum of 4 carbon atoms; in particular wherein a higher level of EB1 in the sample from the subject relative to a standard value or set of standard values predicts sensitivity of the brain neoplasm to the compound of formula I or pharmaceutically acceptable derivative thereof. The invention also provides methods of treatment and kits for use according to the invention.

Abstract: Methods and systems for providing media optimization are described. In one embodiment, a method for providing media optimization involves hosting a webpage at a content source, where the webpage contains media content and an instruction for optimizing the media content using an access network, receiving a request for the webpage at the content source from an end-user device, and sending the media content from the content source to the end-user device through the access network where the media content is optimized according to a technique specified in the instruction. Other embodiments are also described.

Abstract: Methods and systems for providing a zero rating service to an end-user device are described. In one embodiment, a method for providing a zero rating service to an end-user device involves redirecting a request that is directed to a third party URL from an end-user device to a zero rating URL and performing a URL transformation in response to the redirected request. Other embodiments are also described.